Jeremy Chadwick resigned as Chief Operating Officer at Kymera Therapeutics, Inc..
“Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026.”
Kymera Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Kymera Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.”
Kymera Therapeutics, Inc.: Amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-25).
“On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.”
Kymera Therapeutics, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2026-02-26).
“On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement SM , dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.”
Kymera Therapeutics, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at up to $500,000,000 (effective 2026-02-26).
“On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen.”
Kymera Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC (effective 2025-12-09).
“On December 9, 2025, Kymera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives (the “Representatives”) of the underwriters listed in Schedule II thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 7,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a price to the public of $86.00 per share (the “Offering”).”
Leigh Morgan departed as Director at Kymera Therapeutics, Inc..
“On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.”
Joanna Horobin resigned as Director at Kymera Therapeutics, Inc..
“On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.”
Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 2, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.”
Felix J. Baker was appointed as Director and Lead Independent Director at Kymera Therapeutics, Inc..
“On March 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”), the Board appointed Felix J. Baker, Ph.D. to join the Board, effective March 28, 2024.”
Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023.
“On February 22, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2023 and for the fiscal year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.”
Kymera Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 2, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.”
Kymera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $16.5 million.
“. A replay of the webcast will be archived and available following the event. Second Quarter 2023 Financial Results Collaboration Revenues: Collaboration revenues were $16.5 million for the second quarter of 2023 compared to $11.5 million for the second quarter of 2022. Collaboration revenues include revenue from the Company’s Sanofi and Vertex”
Kymera Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
“The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Kymera Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers at the 2023-06-15 meeting.
“The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Kymera Therapeutics, Inc. shareholders approved Election of Class III Director Nominees at the 2023-06-15 meeting.
“The shareholders of the Company elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, for a three-year term ending at the annual meeting of shareholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal.”
Jeremy Chadwick, Ph.D. was appointed as Chief Operating Officer at Kymera Therapeutics, Inc..
“On May 22, 2023, Kymera Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer effective as of May 22, 2023.”
Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 4, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.”
Elaine Caughey departed as Chief Business Officer at Kymera Therapeutics, Inc..
“Elaine Caughey, its Chief Business Officer, will be departing the Company for personal family reasons effective as of April 10, 2023.”
Kymera Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2022.
“On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.”
Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2022.
“On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.”
Kymera Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Kymera Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2022.”
Victor Sandor was appointed as Director at Kymera Therapeutics, Inc..
“On November 1, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Victor Sandor, M.D. to join the Board, effective as of November 3, 2022.”
Donald Nicholson resigned as Director at Kymera Therapeutics, Inc..
“On October 31, 2022, Donald Nicholson, Ph.D., a member of the Board of Directors (the “Board”) of the Company and the Compensation Committee of the Board, notified the Company of his resignation from the Board and all committees thereof, effective November 3, 2022.”
Leigh Morgan was appointed as Director at Kymera Therapeutics, Inc..
“the Board appointed Leigh Morgan to join the Board, effective as of July 6, 2022.”
Steven Hall departed as Director at Kymera Therapeutics, Inc..
“On April 6, 2022, Dr. Steven Hall, a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Compensation Committee of the Board, informed the Company that he does not intend to stand for reelection at the Company’s 2022 annual meeting of stockholders”
John Maraganore was appointed as Director at Kymera Therapeutics, Inc..
“the Board appointed John Maraganore, Ph.D. to join the Board, effective as of January 17, 2022.”
Richard Chesworth departed as Chief Scientific Officer at Kymera Therapeutics, Inc..
“On September 16 th , 2021, Kymera Therapeutics, Inc. (the “Company”) announced that Richard Chesworth, its Chief Scientific Officer, will be departing the Company effective as of October 22 nd 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.